Abstract

The Cancer Therapeutics Program membership includes clinical and basic science researchers whose shared focus is the translation of novel cancer therapies into new standards of care. This includes introduction of novel therapies developed in laboratories within the Abramson Cancer Center. In the period of the current report there has also been an initiative taken with one company (Pfizer) through which Penn investigators have obtained access to selected Pfizer compounds to pursue avenues of mutual interest that would not ordinarily rise to the priority within the company of receiving industry funding. Through this mechanism, the unexpected activity of an activating antibody directed to CD40 in pancreatic cancer has been discovered, as well as activity of a cdk 4/6-directed cell cycle inhibitor in two malignancies. The success of this collaboration is a constructive start to developing models for the optimal interaction of industry and academia in a time of intense scrutiny. For novel therapies that originate from industry sources in general, priority has been placed on the development of therapies for which Program members have scientific expertise regarding the pathways being perturbed or a research interest in defining responsive and refractory subpopulations.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016520-39
Application #
8823497
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-12-01
Budget End
2015-11-30
Support Year
39
Fiscal Year
2015
Total Cost
$113,547
Indirect Cost
$85,971

  Institution

Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104

  Publications

Lang, Fengchao; Sun, Zhiguo; Pei, Yonggang et al. (2018) Shugoshin 1 is dislocated by KSHV-encoded LANA inducing aneuploidy. PLoS Pathog 14:e1007253
Rosenfeld, Aaron M; Meng, Wenzhao; Luning Prak, Eline T et al. (2018) ImmuneDB, a Novel Tool for the Analysis, Storage, and Dissemination of Immune Repertoire Sequencing Data. Front Immunol 9:2107
Kushner, Carolyn J; Hwang, Wei-Ting; Wang, Shiyu et al. (2018) Long-term risk of second malignancies in women after breast conservation therapy for ductal carcinoma in situ or early-stage breast cancer. Breast Cancer Res Treat 170:45-53
Buljan, Vlado A; Graeber, Manuel B; Holsinger, R M Damian et al. (2018) Calcium-axonemal microtubuli interactions underlie mechanism(s) of primary cilia morphological changes. J Biol Phys 44:53-80
Min, Eun Jeong; Safo, Sandra E; Long, Qi (2018) Penalized Co-Inertia Analysis with Applications to -Omics Data. Bioinformatics :
Chang, Changgee; Kundu, Suprateek; Long, Qi (2018) Scalable Bayesian variable selection for structured high-dimensional data. Biometrics :
Pei, Yonggang; Singh, Rajnish Kumar; Shukla, Sanket Kumar et al. (2018) Epstein-Barr Virus Nuclear Antigen 3C Facilitates Cell Proliferation by Regulating Cyclin D2. J Virol 92:
Singh, Rajnish Kumar; Lang, Fengchao; Pei, Yonggang et al. (2018) Metabolic reprogramming of Kaposi's sarcoma associated herpes virus infected B-cells in hypoxia. PLoS Pathog 14:e1007062
Micallef, Ivana N; Stiff, Patrick J; Nademanee, Auayporn P et al. (2018) Plerixafor Plus Granulocyte Colony-Stimulating Factor for Patients with Non-Hodgkin Lymphoma and Multiple Myeloma: Long-Term Follow-Up Report. Biol Blood Marrow Transplant 24:1187-1195
Nicastri, Michael C; Rebecca, Vito W; Amaravadi, Ravi K et al. (2018) Dimeric quinacrines as chemical tools to identify PPT1, a new regulator of autophagy in cancer cells. Mol Cell Oncol 5:e1395504

Showing the most recent 10 out of 1047 publications